1、1.Constant currencies(cc),core results and free cash flow are non-IFRS measures.An explanation of non-IFRS measures can be found on page 40 of the Condensed Interim Financial Report.Unless otherwise noted,all growth rates in this Release refer to same period in prior year.2.Please see detailed guida

2、nce assumptions on page 7.Novartis International AG CH-4002 Basel Switzerland https:/ http:/ FINANCIAL RESULTS|FINANZERGEBNISSE Novartis reports strong Q2 with double-digit sales growth and core margin expansion;raises FY 2025 core operating income guidance Ad hoc announcement pursuant to Art.53 LR

3、Q2 net sales grew+11%(cc1,+12%USD)with core operating income1 up+21%(cc,+20%USD)o Sales growth driven by continued strong performance from Kisqali(+64%cc),Entresto(+22%cc),Kesimpta(+33%cc),Scemblix(+79%cc),Leqvio(+61%cc)and Pluvicto(+30%cc)o Core operating income margin1 reached 42.2%,+340 basis poi

4、nts(cc),mainly driven by higher net sales Q2 operating income grew+25%(cc,+21%USD);net income up+26%(cc,+24%USD)Q2 core EPS1 grew+24%(cc,+23%USD)to USD 2.42 Q2 free cash flow1 of USD 6.3 billion(+37%USD)driven by higher net cash flows from operating activities H1 net sales up+13%(cc,+12%USD)and core

5、 operating income up+24%(cc,+21%USD)Q2 selected innovation milestones:o Pluvicto Phase III PSMAddition study positive readout in PSMA+mHSPC o Vanrafia(atrasentan)FDA accelerated approval for IgAN o OAV101 IT US and EU submissions for SMA o Votoplam Phase II PIVOT-HD study positive readout in Hunting

6、tons disease o Remibrutinib Phase II study positive readout in food allergy Initiating up-to USD 10 billion share buyback to be completed by year-end 2027 Full-year 2025 guidance2 raised for core operating income o Sales expected to grow high single digit(unchanged)o Core operating income expected t